Home › Stocks › NSRX

NSRX — NASUS PHARMA

Reported value held$8.17M
Funds holding (latest)14
SectorHealth Care

What is a 13F filing? Who files one and when · What 13F filings can't tell you

Funds holding (Q3 2026)9
Institutional value$7.84M · 2.12M sh
New / Add / Cut / Exit1 / 1 / 0 / 2 · Updated 2026-11-21
Top-5 / Top-10 concentration98.8% / 100.0%
Institutional holdings change Accumulating +0.1% (+2.40K sh)
Institutional value change Up +5.5%

Fundamentals (SEC EDGAR XBRL)

Financials from SEC company facts, point-in-time aligned to each figure’s EDGAR filing date.

Revenue TTM Revenue YoY Net income TTM Net income YoY ROE (TTM) Gross margin Net margin P/E (TTM) P/E pct P/B P/B pct
— — — — — — — — — — —

Wall Street Analyst Consensus

Ratings, 12-month price target and EPS forecasts from the Nasdaq public analyst feed. · Fetched 2026-11-19

Consensus ratingStrong Buy
Analysts covering—
12-month price target$18.00 (+592.3%)
Last price at fetch$2.60
Forward P/E (FY1)—
Forward P/E (FY2)—
Revision score (quarter)+0.00
Revision score (year)+0.00
Fiscal quarter end Consensus EPS forecast Forward P/E High EPS Low EPS # estimates Revisions (4wk up/down)
Sep 2026 0.00 — 0.00 0.00 1 —
Dec 2026 -0.31 — -0.31 -0.31 1 —
Fiscal year end Consensus EPS forecast Forward P/E High EPS Low EPS # estimates Revisions (4wk up/down)
Dec 2026 -0.84 — -0.84 -0.84 1 —
Dec 2027 -0.81 — -0.81 -0.81 1 —
Dec 2028 -0.37 — -0.37 -0.37 1 —

Forward P/E uses the fetch-time price divided by consensus EPS (quarter annualised ×4). Revision score = (upgrades − downgrades) / estimates, from Nasdaq 4-week counts. Source: Nasdaq analyst data

Last updated: 2026-11-21 · Source: SEC EDGAR Form 13F-HR

As of Q3 2026, 9 SEC-registered investment managers reported holding NSRX (NASUS PHARMA) in their latest 13F filings, with a combined reported value of $7.84M across 2.12M shares. That is +0.1% by share count (+2.40K shares) versus the previous quarter, while reported value moved +5.5%. Ownership is concentrated: the five largest holders account for 98.8% of reported value and the top ten for 100.0%.

Compared with the prior quarter, 1 opened new positions, 1 added to existing stakes, 2 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q3 2026, not real-time trading.

Major shareholders of NASUS PHARMA (NSRX) include Balyasny Asset Management, Cable Car Capital, LP, Velan Capital Investment Management LP, ranked by reported 13F value among the 14 institutional holders on this page.

NSRX is classified in the Health Care sector.

All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.

Institutional Ownership by Quarter

Quarter Funds holding Shares Value QoQ Net Change
Q3 2026 9 2.12M $7.84M +0.1%
Q2 2026 10 2.15M $7.53M +0.6%
Q1 2026 9 2.17M $4.83M +114.2%
Q4 2025 2 2.38K $21.76K -26.6%
Q3 2025 2 3.24K $21.55K —

Over the 5 quarters shown, institutional share counts increased 65432% in aggregate (Q3 2025 → Q3 2026); the largest single-quarter swing was Q1 2026 (+114.2%).

Top Institutional Holders (Q3 2026) — 9 funds

FundSharesValuePortfolio WeightChange
Balyasny Asset Management 898.47K $3.32M 0.01% Hold
Cable Car Capital, LP history 616.08K $2.27M 0.28% Hold
Velan Capital Investment Management LP history 359.39K $1.33M 1.27% Hold
Hudson Bay Capital Management LP 134.77K $497.31K 0.00% Hold
Bleichroeder LP 89.85K $331.54K 0.03% Hold
Renaissance Technologies 14.60K $53.87K 0.00% Add
Pinnacle Financial Group, Inc. 9.71K $35.84K 0.00% New
Morgan Stanley 1.00K $3.69K 0.00% Hold
Caitong International Asset Management Co., Ltd 4 $15 0.00% Hold

↑ Back to the top of the holders list

Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders

Q2 2026 — 10 funds

FundSharesValuePortfolio WeightChange
Balyasny Asset Management 898.47K $3.14M 0.01% Hold
Cable Car Capital, LP history 616.08K $2.16M 0.09% Add
Velan Capital Investment Management LP history 359.39K $1.26M 0.81% Hold
Hudson Bay Capital Management LP 134.77K $471.70K 0.00% Hold
Bleichroeder LP 89.85K $314.47K 0.06% Hold
Citadel Advisors 22.00K $77.01K 0.00% New
XTX Topco Ltd 16.64K $58.24K 0.00% New
Renaissance Technologies 12.20K $42.70K 0.00% New
Morgan Stanley 1.00K $3.50K 0.00% Reduce
Caitong International Asset Management Co., Ltd 4 $14 0.00% New

Q1 2026 — 9 funds

FundSharesValuePortfolio WeightChange
Balyasny Asset Management 898.47K $1.99M 0.01% New
Cable Car Capital, LP history 602.00K $1.34M 0.46% New
Velan Capital Investment Management LP history 359.39K $797.85K 0.50% New
Hudson Bay Capital Management LP 134.77K $299.19K 0.00% New
Bleichroeder LP 89.85K $199.46K 0.03% New
Empery Asset Management, LP 45.80K $101.68K 0.12% New
HRT FINANCIAL LP 38.90K $86.00K 0.00% New
UBS Group AG 3.09K $6.87K 0.00% Add
Morgan Stanley 2.00K $4.44K 0.00% Hold

Q4 2025 — 2 funds

FundSharesValuePortfolio WeightChange
Morgan Stanley 2.00K $18.30K 0.00% Hold
UBS Group AG 378 $3.46K 0.00% Reduce

Q3 2025 — 2 funds

FundSharesValuePortfolio WeightChange
Morgan Stanley 2.00K $13.30K 0.00% New
UBS Group AG 1.24K $8.25K 0.00% New

New Positions (Q3 2026)

Fully Exited (vs previous quarter)

Fund Position History — shares by quarter (top 14 funds)

FundQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Balyasny Asset Management 898.47K 898.47K 898.47K — —
Cable Car Capital, LP 616.08K 616.08K 602.00K — —
Velan Capital Investment Management LP 359.39K 359.39K 359.39K — —
Hudson Bay Capital Management LP 134.77K 134.77K 134.77K — —
Bleichroeder LP 89.85K 89.85K 89.85K — —
Renaissance Technologies 14.60K 12.20K — — —
Pinnacle Financial Group, Inc. 9.71K — — — —
Morgan Stanley 1.00K 1.00K 2.00K 2.00K 2.00K
Caitong International Asset Management Co., Ltd 4 4 — — —
Empery Asset Management, LP — — 45.80K — —
HRT FINANCIAL LP — — 38.90K — —
Citadel Advisors — 22.00K — — —
XTX Topco Ltd — 16.64K — — —
UBS Group AG — — 3.09K 378 1.24K

Download holders (CSV)

FAQ

Which funds hold NSRX?

As of 2026-Q3, 9 institutional funds reported holding NSRX (NASUS PHARMA) in SEC 13F filings, with a combined reported value of $7.84M.

How many shares of NSRX do institutions own?

13F filers reported 2.12M shares of NSRX, worth $7.84M in aggregate at the end of 2026-Q3.

Is institutional ownership of NSRX rising or falling?

Share counts moved +0.1% versus the prior quarter — accumulation.

Who are the top institutional holders of NSRX?

The largest 13F holders are Balyasny Asset Management, Cable Car Capital, LP, Velan Capital Investment Management LP, Hudson Bay Capital Management LP, Bleichroeder LP; the top 25 are ranked at the top of this page.

Who are the major shareholders of NASUS PHARMA?

The major shareholders of NASUS PHARMA (NSRX) by reported 13F value are Balyasny Asset Management, Cable Car Capital, LP, Velan Capital Investment Management LP, Hudson Bay Capital Management LP, Bleichroeder LP, among 14 institutional holders.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.

Embed this stock on your site

Copy the snippet below to show a live "which legendary investors own NSRX" list on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/stocks/NSRX/widget" width="100%" height="640" frameborder="0" loading="lazy" title="HoldingsHub stock holders"></iframe>

Preview the embeddable widget →